Agios Pharmaceuticals (NASDAQ:AGIO) Upgraded to Buy by BidaskClub
Other research analysts have also recently issued research reports about the stock. Cantor Fitzgerald reaffirmed an overweight rating and issued a $70.00 target price (up previously from $64.00) on shares of Agios Pharmaceuticals in a research report on Friday, February 14th. Cowen reaffirmed a buy rating on shares of Agios Pharmaceuticals in a research report on Wednesday, March 4th. Barclays began coverage on shares of Agios Pharmaceuticals in a research report on Wednesday, March 4th. They issued an equal weight rating and a $50.00 target price on the stock. Canaccord Genuity reaffirmed a buy rating and issued a $72.00 target price on shares of Agios Pharmaceuticals in a research report on Friday, May 1st. Finally, JPMorgan Chase & Co. upped their target price on shares of Agios Pharmaceuticals from $72.00 to $82.00 and gave the company an overweight rating in a research report on Monday, May 4th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have assigned a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $63.08.
Shares of AGIO stock opened at $52.78 on Wednesday. The company’s 50-day moving average price is $42.53 and its 200-day moving average price is $43.83. Agios Pharmaceuticals has a twelve month low of $27.77 and a twelve month high of $54.68. The company has a current ratio of 8.41, a quick ratio of 8.27 and a debt-to-equity ratio of 0.17. The stock has a market cap of $3.45 billion, a price-to-earnings ratio of -8.99 and a beta of 2.09.
In other Agios Pharmaceuticals news, insider Christopher Bowden sold 3,583 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $50.01, for a total transaction of $179,185.83. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 3.16% of the stock is owned by corporate insiders.
Several hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its stake in shares of Agios Pharmaceuticals by 16.3% during the first quarter. BlackRock Inc. now owns 4,529,580 shares of the biopharmaceutical company’s stock worth $160,709,000 after buying an additional 636,186 shares during the period. State Street Corp increased its stake in shares of Agios Pharmaceuticals by 1.3% during the first quarter. State Street Corp now owns 1,909,309 shares of the biopharmaceutical company’s stock worth $67,742,000 after buying an additional 24,523 shares during the period. First Trust Advisors LP increased its stake in shares of Agios Pharmaceuticals by 18.4% during the fourth quarter. First Trust Advisors LP now owns 1,533,749 shares of the biopharmaceutical company’s stock worth $73,237,000 after buying an additional 238,728 shares during the period. Farallon Capital Management LLC purchased a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth approximately $59,688,000. Finally, ArrowMark Colorado Holdings LLC increased its stake in shares of Agios Pharmaceuticals by 6.7% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 1,108,401 shares of the biopharmaceutical company’s stock worth $52,926,000 after buying an additional 69,326 shares during the period. Hedge funds and other institutional investors own 98.29% of the company’s stock.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.
Featured Story: What is a Backdoor Roth IRA?
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.